Nikolai Kley

Prior to joining FORMA, Dr. Kley was Vice President and Head of Research at GPC Biotech. Dr. Kley was an early member of the GPC Biotech management team (1999-2007) and played key roles in developing and advancing the company’s genomics, proteomics, chemical proteomics and biology technology platforms, in attracting and managing multimillion dollar government grants and strategic alliances with pharmaceutical companies, and in building GPC Biotech’s preclinical oncology drug discovery pipeline and translational research capabilities. From 1997-1999 he was Director and Vice President, Functional Genomics, at Genome Therapeutics Corporation. Prior to that Dr. Kley was Senior Research Investigator, Group Leader and Head of Tumor Suppressor Program in the Oncology Division at Bristol Myers Squibb Pharmaceutical Research Institute (Princeton), and a Visiting Research Scholar (Research Professor) at Princeton University. Dr. Kley was a postdoctoral fellow in Neuro-Oncology at Massachusetts General Hospital and Harvard Medical School. He received his Ph.D. in Biochemistry from the Max-Planck Institute (Martinsried, Germany) and Ludwig Maximillian University (Munich, Germany), and was a recipient of the Otto Hahn Medal Award (Max Planck Society) and Junior Investigator Award of the National Neurofibromatosis Foundation, which he later also served as member of the scientific advisory board. He received his B.Sc.Hon. in Biochemistry/Physiology from Leeds University (UK) and his earlier education at the European School in Varese, Italy.